DiaSorin S.p.A. (0GZX)

Profile

https://diasoringroup.com/en

DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics segments. Founded in 2000 and headquartered in Saluggia, Italy, the company develops, manufactures, and markets advanced in vitro diagnostic reagent kits and instruments for detecting antibodies, antigens, infectious diseases, and genetic disorders. Notable acquisitions, such as Luminex in 2021, have expanded its portfolio to include innovative technologies like the Luminex 100/200 systems, ARIES platforms, VERIGENE System, xMAP Technology, and companion diagnostics kits for conditions including cystic fibrosis. DiaSorin S.p.A. serves healthcare, life sciences, and diagnostics industries worldwide, with key geographic presence in North America, Europe, and Italy. Employing over 3,271 people, it generated $1,282.9 million in revenue in 2024, translating clinical needs into specialized tools that support laboratories in disease detection and research. With more than 50 years of expertise through its heritage, DiaSorin S.p.A. plays a pivotal role in advancing diagnostic precision and accessibility in the global healthcare landscape.